Intraductal papillary mucinous neoplasm: Overview of management.

Publisher: Royal Australian College of General Practitioners Country of Publication: Australia NLM ID: 101718099 Publication Model: Print Cited Medium: Internet ISSN: 2208-7958 (Electronic) NLM ISO Abbreviation: Aust J Gen Pract Subsets: MEDLINE

Original Publication: East Melbourne, Victoria : Royal Australian College of General Practitioners, [2018]-

Adenocarcinoma, Mucinous*/diagnosis ; Adenocarcinoma, Mucinous*/epidemiology ; Adenocarcinoma, Mucinous*/therapy ; Pancreatic Intraductal Neoplasms*/diagnosis ; Pancreatic Intraductal Neoplasms*/epidemiology ; Pancreatic Intraductal Neoplasms*/therapy; Humans ; Carcinoma, Pancreatic Ductal/therapy ; Carcinoma, Pancreatic Ductal/diagnosis ; Carcinoma, Pancreatic Ductal/epidemiology ; Carcinoma, Papillary/diagnosis ; Carcinoma, Papillary/epidemiology ; Carcinoma, Papillary/therapy ; Risk Factors

Background: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is increasingly being diagnosed incidentally on imaging. It has malignant potential, making it vital to establish the correct diagnosis, assess its malignant risk and follow a management strategy to prevent development of invasive carcinoma of the pancreas.
Objective: This review focuses on the epidemiology, natural history, risk factors, diagnosis and management of IPMN of the pancreas, and will provide practical points for general practitioners.
Discussion: IPMN of the pancreas can transform into invasive pancreatic carcinoma at a low rate of approximately 2%/year. Upon diagnosis of IPMN, it is risk stratified based on the presence of worrisome or high-risk stigmata, which guides further management. Management needs to be individualised based on IPMN and patient factors due to limitations with the current diagnostic tools.

Date Created: 20241105 Date Completed: 20241105 Latest Revision: 20241118

20241119

10.31128/AJGP-05-23-6822

39499841